Boston Scientific Corp. (NYSE:BSX) completed its buyout of Plymouth, Minn.-based Atritech Inc.
Atritech’s CE Mark-approved Watchman device is designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.
The $100 million cash deal, which was announced in January, could reach a value of $375 million with the addition of future milestone payments.